Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
Recruiting
Observational Study
Cardiogenic Shock
Extracorporeal Membrane Oxygenation
Vasopressors
Hemodynamic Management
Critical Care
Heart Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 534 (estimated)
- Sponsor
- Xiaotong Hou · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is:
Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogeni…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
* First-time ECMO initiation.
* Venoarterial ECMO (VA-ECMO) as the initial mode.
Exclusion Criteria:
* Age \<18 years.
* Severe pulmonary hypertension.
* Vasopressor use for non-shock indications (e.g., ble…
Contacts